Scientific and policy challenges to development of an AIDS vaccine

Lancet

Volumn 370, Issue 9581, 2007, Pages 94-101

  Berkley, Seth Franklin ^a   Koff, Wayne Chester ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS 5 VECTOR; ADENOVIRUS VECTOR; CANARYPOX VIRUS VECTOR; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION CONTROL; NONHUMAN; PANDEMIC; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION; VIRUS LOAD;

EID: 34347329085     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61054-X     Document Type: Note

References (65)

1. G8. Africa. Perthshire, Scotland: G8 Gleneagles, 2005. www.fco.gov.uk/Files/kfile/PostG8_Gleneagles_Africa,0.pdf (accessed April 11, 2007).
2. UNAIDS/WHO. AIDS Epidemic Update (2006), Geneva: UNAIDS/WHO, Switzerland. http://data.unaids.org/pub/EpiReport/2006/03-Introduction-2006_EpiUpdate_eng.pdf (accessed April 11, 2007).
3. Salomon J., Hogan D., Stover J., et al. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2 (2005) e16
4. Stover J., Bollinger L., Hecht R., Williams C., and Roca E. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff 26 (2007) 1147-1158
5. HIV Vaccines and Microbicides Resource Tracking Working Group. Adding it all up: funding for HIV vaccine and microbicide development, 2000 to 2005. http://www.hivresourcetracking.org/content/RT_2006_Report_FINAL.pdf (accessed April 11, 2007).
6. Horton R. AIDS: the elusive vaccine. NY Review of Books 51 (Sep 23, 2004) 53-58. http://www.nybooks.com/articles/17400 (accessed April 11, 2007).
7. Addo M., Draenert R., Rathod A., et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2 (2007) e321
8. Betts M., Nason M., West S., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 (2006) 4781-4789
9. Schmitz J., Kuroda M., Santra S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 (1999) 857-860
10. Schmitz J., Johnson R., McClure H., et al. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 79 (2005) 8131-8141
11. Letvin N., Mascola J., Sun Y., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312 (2006) 1530-1533
12. Daniel M., Kirchhoff F., Czajak S., Sehgal P., and Desrosiers R. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 (1992) 1938-1941
13. Wyand M., Manson K., Montefiori D., Lifson J., Johnson R., and Desrosiers R. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73 (1999) 8356-8363
14. Veazey R., Shattock R., Pope M., et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9 (2003) 343-346
15. Parren P., Marx P., Hessell A., et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75 (2001) 8340-8347
16. Koff W., Johnson P., Watkins D., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7 (2006) 19-23
17. Whatmore A., Cook N., Hall G., Sharpe S., Rud E., and Cranage M. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 69 (1995) 5117-5123
18. Baba T., Jeong Y., Pennick D., Bronson R., Greene M., and Ruprecht R. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267 (1995) 1820-1825
19. Wyand M., Manson K., Lackner A., and Desrosiers R. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nat Med 3 (1997) 32-36
20. Rhodes D., Ashton L., Solomon A., et al. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group. J Virol 74 (2000) 10581-10588
21. Evans D., Bricker J., Sanford H., et al. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol 79 (2005) 7707-7720
22. Peng Y., Lin F., Verardi P., Jones L., McChesney M., and Yilma T. Pseudotyped single-cycle simian immunodeficiency viruses expressing gamma interferon augment T-cell priming responses in vitro. J Virol 81 (2007) 2187-2195
23. Lifson J., Piatak Jr. M., Cline A., et al. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge. J Med Primatol 32 (2003) 201-210
24. Gauduin M., Yu Y., Barabasz A., et al. Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J Exp Med 203 (2006) 2661-2672
25. Lifson J., Rossio J., Piatak Jr. M., et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 20 (2004) 772-787
26. Flynn N., Forthal D., Harro C., Judson F., Mayer K., and Para M. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 (2005) 654-665
27. Burton D., Desrosiers R., Doms R., et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 303 (2004) 316
28. Nitayaphan S., Pitisuttithum P., Karnasuta C., et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 190 (2004) 702-706
29. Lee D., Graham B., Chiu Y., et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190 (2004) 903-907
30. Shiver J., and Emini E. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55 (2004) 355-372
31. Kostense S., Koudstaal W., Sprangers M., et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 (2004) 1213-1216
32. Vogels R., Zuijdgeest D., van Rijnsoever R., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003) 8263-8271
33. Roberts D., Nanda A., Havenga M., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 (2006) 239-243
34. Casimiro D., Wang F., Schleif W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 15 (2005) 547-555
35. Burton D., Desrosiers R., Doms R., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 (2004) 233-236
36. Mascola J. Defining the protective antibody response for HIV-1. Curr Mol Med 3 (2003) 209-216
37. Pantophlet R., and Burton D. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24 (2006) 739-769
38. Sattentau Q., and Moore J. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 182 (1995) 185-196
39. Golding H., Zaitseva M., de Rosny E., et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76 (2002) 6780-6790
40. Saphire E., Parren P., Pantophlet R., et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 (2001) 1155-1159
41. Zhou T., Xu L., Dey B., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 (2007) 732-737
42. Sanders R., Venturi M., Schiffner L., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76 (2002) 7293-7305
43. Calarese D., Lee H., Huang C., et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci USA 102 (2005) 13372-13377
44. Ofek G., Tang M., Sambor A., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78 (2004) 10724-10737
45. Cardoso R., Zwick M., Stanfield R., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 (2005) 163-173
46. Zwick M., Labrijn A., Wang M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 (2001) 10892-10905
47. Gorny M., Williams C., Volsky B., et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76 (2002) 9035-9045
48. Yang X., Lee J., Mahony E., Kwong P., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76 (2002) 4634-4642
49. Grundner C., Li Y., Louder M., et al. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331 (2005) 33-46
50. Barnett S., Lu S., Srivastava I., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75 (2001) 5526-5540
51. Pantophlet R., Wilson I., and Burton D. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 77 (2003) 5889-5901
52. Fouts T., Godfrey K., Bobb K., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 99 (2002) 11842-11847
53. Mascola J., Lewis M., Stiegler G., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73 (1999) 4009-4018
54. Anderson R., and Hanson M. Potential public health impact of imperfect HIV type 1 vaccines. J Infect Dis 191 suppl 1 (2005) 85-96
55. Quinn T., Wawer M., Sewankambo N., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342 (2000) 921-929
56. Kijak G., and McCutchan F. HIV diversity, molecular epidemiology, and the role of recombination. Curr Infect Dis Rep 7 (2005) 480-488
57. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., and Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58 (2001) 19-42
58. Fu T., Dubey S., Mehrotra D., et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 23 (2007) 67-76
59. Kiepiela P., Ngumbela K., Thobakgale C., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13 (2007) 46-53
60. Wilson N., Reed J., Napoe G., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80 (2006) 5875-5885
61. Fischer W., Perkins S., Theiler J., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 13 (2007) 100-106
62. Mattapallil J., Douek D., Hill B., Nishimura Y., Martin M., and Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 (2005) 1093-1097
63. Haase A. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5 (2005) 783-792
64. Excler JL, Rida W, Priddy F, et al. Strategy for accelerating development of preventive AIDS vaccines: Screening Test of Concept (STOC) Trials. AIDS (in press).
65. The Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2 (2005) e25